| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Propanedioic acid, 2-[(1R)-3-oxo-1-phenyl-3-[4-(trifluoroMethyl)phenyl]propyl]- manufacturers
- (R)-PS210
-
- $995.00
-
2026-04-22
- CAS:1410101-89-1
- Purity:
- Supply Ability: 10g
|
| | Propanedioic acid, 2-[(1R)-3-oxo-1-phenyl-3-[4-(trifluoroMethyl)phenyl]propyl]- Basic information |
| | Propanedioic acid, 2-[(1R)-3-oxo-1-phenyl-3-[4-(trifluoroMethyl)phenyl]propyl]- Chemical Properties |
| Boiling point | 577.9±50.0 °C(Predicted) | | density | 1.400±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 230 mg/mL (604.77 mM; Need ultrasonic) | | pka | 2.93±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Propanedioic acid, 2-[(1R)-3-oxo-1-phenyl-3-[4-(trifluoroMethyl)phenyl]propyl]- Usage And Synthesis |
| Uses | (R)-PS210, the R enantiomer of PS210 (compound 4h-eutomer), is a substrate-selective allosteric activator of PDK1 with an AC50 value of 1.8 μM. (R)-PS210 targets to the PIF-binding pocket ofPDK1. PIF: The protein kinase C-related kinase 2 (PRK2)-interacting fragment[1]. | | References | [1] Wilhelm A, et al. 2-(3-Oxo-1,3-diphenylpropyl)malonicacidsaspotentallostericligandsof thePIFpocketofphosphoinositide-dependentkinase-1:developmentandprodrugconcept.J Med Chem.2012 Nov 26;55(22):9817-30. DOI:10.1021/jm3010477 |
| | Propanedioic acid, 2-[(1R)-3-oxo-1-phenyl-3-[4-(trifluoroMethyl)phenyl]propyl]- Preparation Products And Raw materials |
|